|
|
|
|
|
|
|
|
|
|
|
23.03.26 - 12:03
|
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026....
|
|
|
|
|
|
|
|
|
11.03.26 - 21:33
|
Why Is Ocugen Stock Soaring Today? (Benzinga)
|
|
|
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $10 price target.
Importance Rank:
1
read more...
|
|
|
|
|
11.03.26 - 15:24
|
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline (24/7 Wall St.)
|
|
|
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders. The call arrives just days after Ocugen completed enrollment in its Phase 3 retinitis pigmentosa trial and reported full-year 2025 financials that reflected both ... Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline
The post Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 13:06
|
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa (GlobeNewswire EN)
|
|
|
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial, topline data will be available in the first quarter of 2027. These data are anticipated to support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027. The European Medicines Agency (EMA) has also provided acceptability of the U.S.-based trial for submission of a Marketing Authorization Application (MAA)....
|
|
|
18.02.26 - 13:06
|
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire EN)
|
|
|
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
